Patents by Inventor Michael P. Arend

Michael P. Arend has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION
    Publication number: 20240002344
    Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.
    Type: Application
    Filed: August 27, 2021
    Publication date: January 4, 2024
    Inventors: Zuhui ZHANG, Xiaoti Zhou, Michael P. Arend, Christian Hauge Kjaergaard
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680047
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 11229637
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 25, 2022
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20210369702
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 2, 2021
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. LIN, Thomas B. NEFF, Qingjian WANG, Volkmar GUENZLER-PUKALL, Lee A. FLIPPIN, Michael P. AREND, Alex MELEKHOV
  • ENHANCED ERYTHROPOIESIS AND IRON METABOLISM
    Publication number: 20210107878
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 15, 2021
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20210060000
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-assocaited conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: March 13, 2020
    Publication date: March 4, 2021
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10927081
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 23, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10646482
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 12, 2020
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20200115344
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20190276408
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 11, 2018
    Publication date: September 12, 2019
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190240213
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: August 22, 2018
    Publication date: August 8, 2019
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 10272078
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: April 30, 2019
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20190022080
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: February 5, 2018
    Publication date: January 24, 2019
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 10118897
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 6, 2018
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10092558
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 9, 2018
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 9918977
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: March 20, 2018
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE
    Publication number: 20170312268
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: February 3, 2017
    Publication date: November 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. Lin, Thamas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Process for making isoquinoline compounds
    Patent number: 9708269
    Abstract: The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 18, 2017
    Assignee: FibroGen, Inc.
    Inventors: Michael D. Thompson, Jung Min Park, Michael P. Arend
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20170190667
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: March 17, 2017
    Publication date: July 6, 2017
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase
    Patent number: 9695170
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 4, 2017
    Assignee: FibroGen, Inc.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin